Cleaning Validation Under Health Canada GMP: Acceptance Criteria, Sampling Strategy, and What Inspectors Flag

Cleaning validation deficiencies are one of the more avoidable problems we see come out of Health Canada pharmaceutical GMP inspections. The core regulatory requirements haven’t changed dramatically in years — the challenge is that the interpretation of those requirements has, particularly around acceptance criteria. Facilities that locked in their cleaning limits a decade ago using the traditional 10-ppm carryover rule are increasingly finding those limits challenged during inspections, and for good reason.

If your multi-product manufacturing site hasn’t revisited its cleaning validation master plan since EMA released its 2014 guidance on health-based exposure limits — guidance that Health Canada references in its own expectations — there’s a real chance you have a gap worth addressing internally before an inspector identifies it for you.

The Regulatory Basis: What Health Canada Actually Requires

Health Canada’s GMP requirements for pharmaceutical drug products sit primarily in Division 2 of Part C of the Food and Drug Regulations, supplemented by the Good Manufacturing Practices Guidelines (GUI-0001). For active pharmaceutical ingredients, ICH Q7 is the relevant framework, and Health Canada has formally adopted it.

Neither document prescribes cleaning validation procedures in granular, step-by-step detail. What sections C.02.007 through C.02.012 do require — broadly — is that premises, equipment, and utensils be maintained in a clean and sanitary condition, and that written procedures be established and followed. The “established and followed” language is where cleaning validation enters the picture. Health Canada inspectors operate on the principle that if you can’t demonstrate your cleaning procedure actually works, you can’t credibly claim your equipment is clean.

The more specific technical expectations come from three sources: Health Canada’s alignment with ICH Q7 (for APIs), the 2014 EMA/CHMP guideline on setting health-based exposure limits, and — critically — your own cleaning validation master plan. That last document is frequently one of the first things inspectors request on day one of a compliance inspection.

Acceptance Criteria: Why the 10-PPM Rule Is No Longer Enough

This is where cleaning validation gets genuinely complicated, and where the widest gap exists between older programs and current expectations.

The traditional acceptance criteria were straightforward to apply:

• 10-ppm carryover: No more than 10 parts per million of product A may appear in the minimum daily dose of product B
• 1/1,000th of minimum therapeutic dose: The carryover in the maximum daily dose of product B must be less than 1/1,000th of the minimum therapeutic dose of product A
• Visually clean: Equipment must appear clean to the naked eye after the cleaning procedure

These criteria are simple to calculate and easy to document. The problem is they’re not toxicologically grounded. A cleaning limit derived from the 10-ppm rule for a highly potent compound — say, an oncology API with a Permitted Daily Exposure (PDE) of 0.15 µg/day — can be orders of magnitude higher than what’s actually safe. A 10-ppm carryover limit for such a compound may represent 1,000 times the toxicologically acceptable daily exposure. That’s not a theoretical concern; it’s a real risk in multi-product facilities manufacturing both low- and high-potency products.

Health Canada has aligned with EMA and ICH guidance in expecting manufacturers to use health-based exposure limits (HBELs) — specifically PDE values — as the basis for cleaning acceptance criteria where toxicologically appropriate. A PDE is derived from the compound’s toxicological profile: the no-observed-adverse-effect level (NOAEL), a composite assessment factor, and adjustments for body weight and absorption route. The resulting limit is specific to that compound’s hazard, not a generic threshold applied uniformly.

In practice, this means your cleaning acceptance criteria should now include:

1. A documented PDE value for each product — sourced from the API manufacturer’s safety data package, a published EMA assessment (EMA has published PDEs for several common APIs), or an internal toxicological assessment prepared by a qualified expert
2. A calculated Maximum Allowable Carryover (MACO) for each product pair, based on the PDE and the batch size or shared equipment surface area
3. A corresponding analytical limit expressed in measurable units — typically µg/swab or µg/mL in rinse samples — that confirms the MACO has been met
4. Visual cleanliness as an additional, non-waivable check regardless of analytical results

If you’re currently running a 10-ppm-only program, the corrective path isn’t necessarily to abandon all existing limits. For many low-potency, low-solubility products, a proper HBEL assessment may confirm that 10 ppm is actually conservative relative to the PDE. But that comparison has to be documented and justified, not assumed. Health Canada inspectors want to see the evaluation on file, not hear that “we’ve always done it this way.”

Sampling Strategy: Where Programs Most Often Fall Apart

Acceptance criteria get most of the intellectual attention in cleaning validation discussions, but sampling strategy is where programs actually break down during inspections. Three areas consistently generate observations.

Swab recovery studies. Your acceptance criterion is only meaningful if you know how efficiently your swab method recovers residue from the equipment surface. Recovery factors below 70% on stainless steel — and particularly below 50% on harder-to-clean materials like Teflon, PTFE gaskets, or rubber seals — need to be either corrected through method optimization or formally accounted for in your limit calculation (i.e., dividing the analytical limit by the recovery factor). Health Canada inspectors look specifically for documented recovery studies conducted on representative surface coupons using the exact swab type, solvent, and technique specified in your analytical procedure. A recovery study done with a different solvent concentration than what’s used in practice is not a valid study.

Worst-case surface selection. You can’t swab every square centimetre of a manufacturing vessel, and you’re not expected to. But you do need a documented, scientifically justified rationale for which surfaces you swab — and those surfaces must represent genuine worst-case locations: hardest to reach, most likely to retain product residue, most difficult to clean. Welds, dead legs in piping, the underside of agitator blades, tube bends, pump heads, and product-contact surfaces at vessel bottoms are where inspectors look to see your samples taken. If your sampling plan consistently targets flat, accessible surfaces while ignoring complex geometries, that rationale will be challenged.

Dirty hold time and clean hold time validation. These two parameters are absent from a surprising number of cleaning validation programs. Dirty hold time (DHT) is the maximum elapsed time between the end of manufacturing and the start of the cleaning procedure — validated to demonstrate that residue doesn’t become significantly harder to remove as it dries or polymerizes on equipment surfaces. Clean hold time (CHT) is the maximum time cleaned equipment may be stored before use — validated to show that microbial re-contamination doesn’t occur during that interval. Both need to be formally validated and formally linked to your manufacturing scheduling controls. If a batch record shows equipment held dirty for 36 hours against a validated DHT of 24 hours, that’s a deviation — and an inspector who checks the timestamps will find it.

What Health Canada Inspectors Actually Flag

From the patterns visible across multi-product pharmaceutical and NHP manufacturing facilities, the most frequent cleaning validation citations fall into five categories.

Missing or inadequate revalidation triggers. Your cleaning validation master plan — or the relevant SOP — should define the circumstances that require revalidation: introduction of a new product to shared equipment, a formulation change, a change in cleaning agent or concentration, equipment replacement or significant repair, a change in batch size, or any investigation that points to a cleaning procedure failure. Inspectors want these criteria defined proactively, not assembled after a deviation has already occurred. Seeing “revalidation triggers” left as a placeholder in a template document is a common finding.

Weak bracketing justifications. Multi-product facilities typically validate cleaning using a “worst-case” representative product rather than exhaustively validating every product pair. That’s an accepted and practical approach — but the bracketing argument must be rigorous. It must demonstrate that the chosen worst-case product is worst-case across all the relevant dimensions simultaneously: lowest solubility, highest potency (lowest PDE), and greatest difficulty of cleaning from equipment surfaces. A product chosen because it “seemed hardest to clean” without documented comparison across potency and solubility is unlikely to survive scrutiny.

Analytical methods not validated at cleaning concentrations. The analytical method used to evaluate cleaning samples — whether HPLC, UV spectroscopy, TOC, or another technique — must be validated (or at minimum verified for fitness-for-purpose) at the concentration range relevant to your acceptance criterion. A method validated for product release testing at concentrations of 0.1–1 mg/mL is not automatically valid for detecting cleaning residue at 0.001–0.01 µg/mL. Linearity, detection limit, quantitation limit, and specificity all need to be established at cleaning-relevant concentrations. This is one of the more technical gaps that appears during inspections of smaller facilities.

Absence of a cleaning validation master plan. Facilities — particularly smaller NHP manufacturers operating under the Natural Health Products Regulations (NHPR) — sometimes have individual cleaning validation protocols on file but no overarching master plan that describes the overall strategy, scope, acceptance criteria philosophy, and equipment inventory in scope. Health Canada inspectors increasingly request the master plan as a starting document. Without it, they reconstruct your approach from individual protocols, and inconsistencies between them become visible quickly.

Microbial contamination not addressed. Chemical residue dominates the focus of most cleaning validation programs. But equipment that tests clean for chemical residue can still harbour microbial contamination — particularly in areas where moisture accumulates and biofilm can form during extended clean hold times. For products with tight microbial specifications, sterile drug products, or any product where contamination of the subsequent batch with microorganisms is a meaningful risk, cleaning validation should include documented evidence that the cleaning and drying procedure is sufficient to prevent biofilm formation within the validated CHT. This is an area where Health Canada expectations are tightening.

Building a Program That Holds Up

A cleaning validation program that survives a Health Canada inspection isn’t necessarily elaborate. It’s complete. The core elements are:

• A cleaning validation master plan covering overall strategy, equipment in scope, acceptance criteria methodology, and revalidation triggers
• Documented PDE/HBEL assessments for each product, or a formally justified argument showing legacy limits remain adequate relative to the HBEL
• Swab recovery studies for all surface material types used in product-contact equipment
• Sampling plans with explicit worst-case surface justification and documented sample location maps
• Validated dirty hold times and clean hold times, with linkage to manufacturing scheduling controls
• Analytical methods validated at cleaning-relevant concentration ranges
• A change control connection ensuring that equipment changes, product additions, and procedure modifications trigger the appropriate revalidation steps

If you’re conducting a gap assessment against current Health Canada expectations, a phased approach — prioritizing highest-risk products and most-shared equipment first — is a defensible strategy, provided the gap assessment itself is documented and your remediation timeline is realistic.

Our team works with pharmaceutical manufacturers and NHP licence holders across Canada on cleaning validation programs: from master plan development and HBEL assessments to sampling strategy design and analytical method validation support. If you’re not confident your current program reflects what Health Canada inspectors are looking for today, an internal gap assessment before your next inspection is time well spent.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• ISO 17025-accredited analytical testing for pharmaceutical and NHP manufacturers — Contract laboratory services for method validation, cleaning verification sampling, and raw material testing in support of Health Canada GMP compliance
• EU GMP and REACH compliance for manufacturers expanding into European markets — Regulatory consulting for Canadian pharmaceutical and health product companies entering the EU